- Home
- SERV vs GYRE Comparison
SERV vs GYRE Comparison
Compare SERV & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SERV
- GYRE
- Stock Information
- Founded
- SERV 2017
- GYRE 2002
- Country
- SERV United States
- GYRE United States
- Employees
- SERV N/A
- GYRE N/A
- Industry
- SERV Industrial Specialties
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- SERV Consumer Discretionary
- GYRE Health Care
- Exchange
- SERV Nasdaq
- GYRE Nasdaq
- Market Cap
- SERV 795.0M
- GYRE 755.7M
- IPO Year
- SERV N/A
- GYRE N/A
- Fundamental
- Price
- SERV $8.66
- GYRE $7.58
- Analyst Decision
- SERV Buy
- GYRE Strong Buy
- Analyst Count
- SERV 4
- GYRE 2
- Target Price
- SERV $18.33
- GYRE $17.00
- AVG Volume (30 Days)
- SERV 5.9M
- GYRE 53.3K
- Earning Date
- SERV 11-12-2025
- GYRE 11-07-2025
- Dividend Yield
- SERV N/A
- GYRE N/A
- EPS Growth
- SERV N/A
- GYRE N/A
- EPS
- SERV N/A
- GYRE 0.04
- Revenue
- SERV $1,944,483.00
- GYRE $107,265,000.00
- Revenue This Year
- SERV $133.16
- GYRE $15.25
- Revenue Next Year
- SERV $795.05
- GYRE $33.14
- P/E Ratio
- SERV N/A
- GYRE $192.89
- Revenue Growth
- SERV 15.76
- GYRE 2.13
- 52 Week Low
- SERV $4.66
- GYRE $6.11
- 52 Week High
- SERV $24.35
- GYRE $14.42
- Technical
- Relative Strength Index (RSI)
- SERV 28.69
- GYRE 45.30
- Support Level
- SERV $8.55
- GYRE $7.43
- Resistance Level
- SERV $9.91
- GYRE $7.81
- Average True Range (ATR)
- SERV 0.82
- GYRE 0.35
- MACD
- SERV -0.23
- GYRE -0.03
- Stochastic Oscillator
- SERV 14.66
- GYRE 30.00
About SERV Serve Robotics Inc. Common Stock
Serve Robotics Inc is developing next-generation robots for last-mile delivery services. It design, develop and operate low-emissions robots on AI-powered robotics mobility platform, that serve people in public spaces, starting with food delivery. Its first product is a zero-emission robot that serves people in public areas, Starting with food delivery. It has developed an AI-robotics mobility platform, with last-mile delivery in cities as its first application.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.